Literature DB >> 35786619

Therapeutic Effect of Crocin on the NASH Model by Targeting the Fas Receptor Signaling Pathway.

Seyyed Ali Mard1, Feryal Savari2, Anahita Rezaie3, Maryam Khosravi4.   

Abstract

BACKGROUND: The role of hepatocyte apoptosis and inflammation has been implicated in the progression of nonalcoholic steatohepatitis (NASH). Overproduction of reactive oxygen species (ROS) appears to accelerate these pathways through the activation of Fas receptor signaling. Therefore, we explored the hepatoprotective effects of crocin as a strong free radical scavenger against oxidative damages leading to NASH development.
METHODS: Thirty-two male mice were randomly divided into control, NASH, NASH + crocin, and crocin groups. They received an intraperi- toneal injection of crocin twice a week, for 3 weeks. For NASH model induction, the animals were fed with a Western diet and exposed to cigarette smoke for 8 weeks. At the end of the experiment, liver histology, biochemical, and biomolecular analyses were done to evaluate the antioxidant, anti-inflammatory, and anti-apoptotic activities of crocin in the NASH model.
RESULTS: Evaluation of the features of the NASH model revealed steatosis, inflammatory infiltrate, and ballooning degeneration. Metabolic dysfunction was associated with elevated serum levels of the lipid profile and decreased hepatic liver enzymes. The increased content of malondialdehyde (MDA) and reduced antioxidant activities confirmed hepatotoxicity induction. There was a significant increase in expression level of Fas, caspase 3, and NF-κB genes that was also associated with elevation in hepatic TNF-α content. Moreover, expression the of Fas receptor protein was significantly detected on the hepatocyte membrane. Treatment with crocin effectively improved NASH-related parameters, and the histopathological findings were also parallel with the resulting changes.
CONCLUSION: Crocin can be introduced as a candidate hepatoprotective agent against NASH by virtue of its anti-inflammatory, antioxi- dant, and anti-apoptotic properties, possibly through regulation of the Fas death receptor pathway.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35786619      PMCID: PMC9319775          DOI: 10.5152/tjg.2022.21088

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  35 in total

1.  Crocin potentiates antioxidant defense system and improves oxidative damage in liver tissue in diabetic rats.

Authors:  Habib Yaribeygi; Mohammad Taghi Mohammadi; Amirhossein Sahebkar
Journal:  Biomed Pharmacother       Date:  2017-12-27       Impact factor: 6.529

2.  Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Zobair M Younossi; Rohit Loomba; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Naga P Chalasani; Quentin M Anstee; Kris V Kowdley; Jacob George; Zachary D Goodman; Keith Lindor
Journal:  Hepatology       Date:  2018-07       Impact factor: 17.425

3.  Crocin, a natural product attenuates lipopolysaccharide-induced anxiety and depressive-like behaviors through suppressing NF-kB and NLRP3 signaling pathway.

Authors:  Lang Zhang; Rahul Previn; Liang Lu; Ri-Fang Liao; Yi Jin; Ri-Kang Wang
Journal:  Brain Res Bull       Date:  2018-09-01       Impact factor: 4.077

Review 4.  Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.

Authors:  Naim Alkhouri; Christine Carter-Kent; Ariel E Feldstein
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 3.869

Review 5.  Apoptosis and necrosis in the liver.

Authors:  Maria Eugenia Guicciardi; Harmeet Malhi; Justin L Mott; Gregory J Gores
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

Review 6.  Relationship between Diet and Non-alcoholic Fatty Liver Disease: A Review Article.

Authors:  Parvin Mirmiran; Zeynab Amirhamidi; Hanieh-Sadat Ejtahed; Zahra Bahadoran; Fereidoun Azizi
Journal:  Iran J Public Health       Date:  2017-08       Impact factor: 1.429

Review 7.  A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease.

Authors:  Zhonge Chen; Rong Yu; Ying Xiong; Fangteng Du; Shuishan Zhu
Journal:  Lipids Health Dis       Date:  2017-10-16       Impact factor: 3.876

8.  Serum Malondialdehyde is Associated with Non-Alcoholic Fatty Liver and Related Liver Damage Differentially in Men and Women.

Authors:  Shira Zelber-Sagi; Dana Ivancovsky-Wajcman; Naomi Fliss-Isakov; Michal Hahn; Muriel Webb; Oren Shibolet; Revital Kariv; Oren Tirosh
Journal:  Antioxidants (Basel)       Date:  2020-07-02

9.  Antifibrotic effects of crocin on thioacetamide-induced liver fibrosis in mice.

Authors:  Mardi M Algandaby
Journal:  Saudi J Biol Sci       Date:  2016-10-13       Impact factor: 4.219

10.  Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.

Authors:  Michelle L Boland; Stephanie Oldham; Brandon B Boland; Sarah Will; Jean-Martin Lapointe; Silvia Guionaud; Christopher J Rhodes; James L Trevaskis
Journal:  World J Gastroenterol       Date:  2018-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.